pentoxifylline has been researched along with Ventricular Dysfunction, Left in 9 studies
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent trials have indicated a beneficial effect of pentoxifylline on measures of inflammation and markers of cardiac dysfunction in people with heart failure." | 8.82 | Pentoxifylline for heart failure: a systematic review. ( Batchelder, K; Mayosi, BM, 2005) |
| "Pentoxifylline has more beneficial potencies in reducing adverse events after coronary artery bypass graft using cardiopulmonary bypass, than what are known." | 6.80 | Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%). ( Abbasi, K; Bina, P; Boroumand, MA; Fehri, A; Karimi, AA; Mansourian, S, 2015) |
| "Recent trials have indicated a beneficial effect of pentoxifylline on measures of inflammation and markers of cardiac dysfunction in people with heart failure." | 4.82 | Pentoxifylline for heart failure: a systematic review. ( Batchelder, K; Mayosi, BM, 2005) |
| "Pentoxifylline has more beneficial potencies in reducing adverse events after coronary artery bypass graft using cardiopulmonary bypass, than what are known." | 2.80 | Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%). ( Abbasi, K; Bina, P; Boroumand, MA; Fehri, A; Karimi, AA; Mansourian, S, 2015) |
| "Treatment with pentoxifylline (P = 0." | 2.70 | The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. ( Bergemann, A; Candy, G; Hopley, M; Sareli, P; Skudicky, D; Sliwa, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mann, DL | 2 |
| Mansourian, S | 1 |
| Bina, P | 1 |
| Fehri, A | 1 |
| Karimi, AA | 1 |
| Boroumand, MA | 1 |
| Abbasi, K | 1 |
| Desplantie, O | 1 |
| Tremblay-Gravel, M | 1 |
| Avram, R | 1 |
| Marquis-Gravel, G | 1 |
| Ducharme, A | 1 |
| Jolicoeur, EM | 1 |
| Özçem, B | 1 |
| Cerit, L | 1 |
| Şahin, T | 1 |
| Akyüz, M | 1 |
| Duygu, H | 1 |
| Batchelder, K | 1 |
| Mayosi, BM | 1 |
| Skudicky, D | 2 |
| Sliwa, K | 2 |
| Bergemann, A | 2 |
| Candy, G | 2 |
| Sareli, P | 2 |
| Negrusz-Kawecka, M | 1 |
| Hopley, M | 1 |
5 reviews available for pentoxifylline and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Innate immunity and the failing heart: the cytokine hypothesis revisited.
Topics: Adaptive Immunity; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Autoantibodies; Autoim | 2015 |
The Medical Treatment of New-Onset Peripartum Cardiomyopathy: A Systematic Review of Prospective Studies.
Topics: Bromocriptine; Cardiomyopathies; Echocardiography; Female; Humans; Hydrazones; Pentoxifylline; Pregn | 2015 |
Inflammatory mediators and the failing heart: past, present, and the foreseeable future.
Topics: Animals; Antibodies, Monoclonal; Antirheumatic Agents; Clinical Trials as Topic; Cytokines; Disease | 2002 |
Pentoxifylline for heart failure: a systematic review.
Topics: Double-Blind Method; Heart Failure; Humans; Pentoxifylline; Prospective Studies; Randomized Controll | 2005 |
[The role of TNF-alpha in the etiopathogenesis of heart failure].
Topics: Cardiomyopathy, Dilated; Etanercept; Heart Failure; Humans; Immunoglobulin G; Immunologic Factors; P | 2002 |
3 trials available for pentoxifylline and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%).
Topics: Administration, Oral; Aged; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Myocardial In | 2015 |
Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline.
Topics: Adult; Apoptosis; Biomarkers; Cardiomyopathy, Dilated; Case-Control Studies; Double-Blind Method; fa | 2000 |
The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy.
Topics: Adult; Cardiomyopathies; Cardiotonic Agents; Enzyme Inhibitors; Female; Humans; Pentoxifylline; Preg | 2002 |
1 other study available for pentoxifylline and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%).
Topics: Coronary Artery Bypass; Humans; Pentoxifylline; Ventricular Dysfunction, Left | 2015 |